Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

National Taiwan University

Status and phase: Completed; Phase 2

Conditions: NSCLC

Treatments: Drug: Docetaxel Plus CDDP

Study type: Interventional

Funder types: Other

Identifiers

NCT00172380

930911

Details and patient eligibility

About

To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.

Enrollment: 41 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed NSCLC, respectable NSCLC stage IIIa T1-2 N2 or or unresectable stage IIIb 2.KPS>70% 3.Hb>10g/dl,ANC>2.0x109/L,Plt.>100x109/L4.T-bil.<1xULN,creatinine<1xULN,creatinine clearance >60 ml/min,GPT/GOT<2.5xULN,ALP<5xULN

Exclusion criteria

• 1.Brain meta.2..Prior surgery,R/T, C/t or immunotherapy for NSCLC

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

41 participants in 1 patient group

docetaxel and cisplatin

Experimental group

Description:

docetaxel 36mg/m2 and cisplatin 75mg/m2

Treatment:

Drug: Docetaxel Plus CDDP